Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00183612 · ClinicalTrials.gov registry record · NA
Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents
A NA study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- NA
- Development phase
- 68
- Enrollment target
NCT00183612: Clinical Trial NA study, sponsored by Massachusetts General Hospital.
NCT00183612 is a NA study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 68 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00183612, a NA study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- NA
- Development phase
- 68 participants
- Enrollment target
Study Summary
This study will examine the safety and effectiveness of the antipsychotic drug olanzapine in children and adolescents with bipolar disorder or psychosis.
Interventions
- DRUG Olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2000-05 |
| Est. Completion | 2007-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00183612
The ClinicalTrials.gov registry entry for NCT00183612 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Olanzapine is the first listed.
NCT00183612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00183612 about?
NCT00183612 is a clinical study titled "Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents". This study will examine the safety and effectiveness of the antipsychotic drug olanzapine in children and adolescents with bipolar disorder or psychosis.
What is the current status of trial NCT00183612?
This trial is currently terminated. It is a NA study. The enrollment target is 68 participants. The study started on 2000-05. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00183612?
The interventions under investigation include: Olanzapine (DRUG).
Who is sponsoring clinical trial NCT00183612?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.